Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05032183
Title Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

lymphoblastic lymphoma

B-cell acute lymphoblastic leukemia

T-cell acute lymphoblastic leukemia

Therapies

Cytarabine + Filgrastim + Methotrexate + Rituximab + Tagraxofusp-erzs

Cyclophosphamide + Dexamethasone + Mesna + Methotrexate + Rituximab + Tagraxofusp-erzs + Vincristine Sulfate

Tagraxofusp-erzs

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.